LEXINGTON, Mass., May 21, 2026
Accent Therapeutics has announced the presentation of a Trial in Progress poster for its ongoing Phase 1/2 clinical study of ATX-295 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the company’s advancement of a potentially best-in-class oral KIF18A inhibitor for the treatment of patients with advanced or metastatic solid tumors. The clinical-stage biopharmaceutical company is developing ATX-295 as a precision oncology therapy targeting tumors characterized by chromosomal instability, an area increasingly recognized as a major vulnerability in aggressive cancers such as high-grade serous ovarian cancer (HGSOC) and squamous non-small cell lung cancer (sqNSCLC). The ASCO presentation further positions Accent Therapeutics within the growing field of targeted oncology drug development focused on highly selective molecular therapies for difficult-to-treat cancers.
ATX-295 Targets Chromosomal Instability in Cancer
ATX-295 is designed to inhibit KIF18A, a mitotic kinesin motor protein essential for cell division in tumors exhibiting chromosomal instability and aneuploidy. According to Accent Therapeutics, preclinical research has demonstrated that KIF18A inhibition selectively induces rapid cancer cell death in tumors with abnormal chromosome numbers while sparing healthy cells with normal chromosomal structures. This differentiated mechanism has generated growing scientific interest because it may provide a highly targeted treatment strategy with reduced toxicity compared with traditional chemotherapy approaches.
The ongoing first-in-human Phase 1/2 clinical study (NCT06799065) is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ATX-295 in patients with locally advanced or metastatic solid tumors. The study includes cancers with high unmet need, particularly ovarian cancer and squamous non-small cell lung cancer, where effective targeted treatment options remain limited. The clinical program consists of an initial dose-escalation phase aimed at determining the recommended Phase 2 dose (RP2D), followed by a dose-expansion phase evaluating early efficacy signals across multiple tumor populations. The study is currently open and actively enrolling patients.
Jason Sager, M.D., Chief Medical Officer of Accent Therapeutics, stated that KIF18A inhibition represents a differentiated strategy for exploiting a fundamental weakness present in chromosomally unstable tumors. He noted that ATX-295 is supported by a strong and expanding body of preclinical evidence and emphasized the company’s goal of delivering a meaningful new targeted therapy option for patients with cancers that currently have limited treatment alternatives.
Advertisement
ASCO 2026 Highlights Precision Oncology Innovation
The upcoming ASCO 2026 presentation will focus on the scientific rationale and clinical development strategy supporting ATX-295 as a next-generation precision oncology candidate. The Trial in Progress poster, titled “A Phase 1/2 First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients with Advanced or Metastatic Solid Tumors, Including Ovarian Cancer,” will be presented during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session on May 30, 2026, in Chicago.
ASCO remains one of the most influential global oncology conferences, with pharmaceutical and biotechnology companies using the meeting to showcase breakthrough clinical data, innovative therapeutic platforms, and next-generation cancer treatment strategies. Accent Therapeutics’ inclusion at ASCO reflects increasing scientific and commercial interest in therapies targeting genomic instability and tumor-specific mitotic mechanisms, areas viewed as highly promising for future oncology innovation.
Precision Cancer Therapies Continue Expanding
Accent Therapeutics continues to build its pipeline around novel small molecule precision oncology therapies designed to address cancers driven by genomic and chromosomal instability. The company retains full worldwide rights to the ATX-295 program and aims to expand development opportunities across multiple solid tumor indications. Industry analysts continue to identify precision oncology and targeted mitotic inhibitors among the fastest-growing areas in cancer drug development due to their potential to improve efficacy while minimizing systemic toxicity.
The advancement of ATX-295 further highlights the rapidly evolving landscape of oncology biotechnology, where highly selective molecular therapies are increasingly shaping the future of personalized cancer treatment and driving substantial scientific investment across the global biopharmaceutical sector.
Source: Accent Therapeutics press release
